RayzeBio’s IPO will support pivotal testing of a targeted radiopharmaceutical for cancer patients who progress after treatment with Novartis’s Lutathera. Neumora will apply its IPO cash toward Phase 3 testing of a depression drug with a novel mechanism of action.
USA: Navacaprant, a new once-daily kappa opioid receptor antagonist, may cause a significant reduction of depression and anhedonia symptoms in participants with moderate-to-severe major depressive.
An experimental antidepressant developed by Neumora Therapeutics has shown promising results in a phase 2 trial, leading the company to plan its pathway to phase 3 testing.
Efficacy of novel drug proven in MDD study europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.
Softbank-backed Neumora Therapeutics' experimental drug navacaprant has helped reduce symptoms of depression in patients with moderate-to-severe forms of the disorder in a mid-stage trial, the company said on Tuesday.